Melissa Epperly - 01 Feb 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Issuer symbol
ZNTL
Transactions as of
01 Feb 2023
Transactions value $
$0
Form type
4
Filing time
01 Feb 2023, 18:07:27 UTC
Previous filing
03 Oct 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +101,957 +34% $0 399,899 01 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +148,043 $0 148,043 01 Feb 2023 Common Stock 148,043 $23.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 Includes 399 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2022.
F3 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.